Compare Vaxcyte Inc. Common Stock (PCVX) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vaxcyte Inc. Common Stock vs Schwab US Large Cap Growth ETF — how do they compare? Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B), while Schwab US Large Cap Growth ETF trades at $35.59 (market cap $65.41B). The key difference: Schwab US Large Cap Growth ETF is far larger — about 6.2× Vaxcyte Inc. Common Stock's market cap, and Schwab US Large Cap Growth ETF is more actively traded (6,607,358 versus 2,644,694). Which is the better fit depends on your goals — on Pluang, investors hold Vaxcyte Inc. Common Stock for 0 Days and Schwab US Large Cap Growth ETF for 52 Days on average.
| PCVX | SCHG | |
|---|---|---|
Market Cap | $10.51B | $65.41B |
Volume | 2,644,694 | 6,607,358 |
Sector | Health | Sector/Thematic |
52-Week High | $73.82 | $36.93 |
52-Week Low | $40.32 | $28.10 |
Typical Hold Time | 0 Days | 52 Days |
Enterprise Value | $9.14B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SCHG trades at $36.59 with no daily change, showing stability amid a bullish technical signal from moving averages while oscillators remain neutral. The ETF maintains strong institutional interest despite a recent 20% position reduction by Corient Private Wealth. Recent news highlights SCHG's competitive positioning among large-cap growth ETFs with its 0.03% expense ratio and concentration in megacap technology stocks.
The outlook remains positive given SCHG's historical outperformance versus the S&P 500, though concentration risk in top holdings and potential valuation concerns warrant monitoring. Growth investors may benefit from the ETF's low-cost exposure to leading US companies, but should be aware of narrowing performance gaps with broader market alternatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vaxcyte Inc. Common Stock
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
